translational-safety

Pharmacovigilance signal detection from FAERS data uses disproportionality measures like PRR, ROR, and IC to identify potential safety signals. This process analyzes FAERS reporting metrics to systematically evaluate adverse event risks.

Grading clinical adverse events using CTCAE v5 standardizes safety assessments across hepatic, renal, and cardiac organ systems. This approach evaluates clinical and laboratory safety data to identify organ-specific toxicity risks.

You can screen candidate drugs for CYP metabolism risk and drug-drug interactions by evaluating metabolic liabilities. This screening identifies potential off-target safety panels and CYP enzyme profile risks.

This safety pharmacology workflow requires structured clinical lab data, omics features, and FAERS reporting metrics. Structured analysis of these inputs is necessary to identify potential safety signals and toxicity risks.

Identify organ-specific safety biomarkers in translational medicine workflows by integrating clinical adverse event grading with metabolic liability screening. This evaluates drug-drug interactions, CYP enzyme profiles, and toxicity risks.